FreeTheAI

Novavax and Healthcare Growth Stocks Drop as Treasury Yields Rise

BearishMedium impact
NVAX$11.26 −12.17%OCUL$6.87 −6.91%QDEL$12.91 −7.19%

Shares of healthcare and biotechnology companies fell sharply during afternoon trading as climbing Treasury yields weighed on high-growth assets. Novavax, Inc. (NASDAQ:NVAX) dropped 12.17% to $11.26, while Ocular Therapeutix Inc (NASDAQ:OCUL) fell 6.91% to $6.87 and QuidelOrtho Corporation (NASDAQ:QDEL) declined 7.19% to $12.91.

Higher interest rates increase the discount rate applied to future corporate earnings, reducing the present value of expected cash flows. This pressure particularly impacts clinical-stage and capital-intensive healthcare firms, which depend on borrowing money to fund long-term research and development. Investors shifted funds away from higher-risk assets toward Treasury securities and blue-chip stocks.

Despite the daily decline, Novavax remains up 57.1% year-to-date, trading 12.6% below its 52-week high of $12.82 set in October 2026. The company's stock has experienced high volatility over the past year, including a 24.4% surge eight months ago following a fourth-quarter profit of $0.11 per share on revenue of $147.1 million. However, long-term returns reflect broader struggle, with a $1,000 investment from five years ago now valued at $67.37.

Key points

  • Novavax, Inc. (NASDAQ:NVAX) fell 12.17% to $11.26 as rising Treasury yields reduced market appetite for growth stocks.
  • Ocular Therapeutix Inc (NASDAQ:OCUL) dropped 6.91% to $6.87, and QuidelOrtho Corporation (NASDAQ:QDEL) fell 7.19% to $12.91.
  • Higher interest rates raise discount rates on future earnings, harming early-stage healthcare firms relying on debt financing.
  • Novavax is up 57.1% year-to-date but remains 12.6% below its 52-week high of $12.82 set in October 2026.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Novavax stock fall?

Novavax stock fell as rising Treasury yields put pressure on capital-intensive healthcare growth equities. Higher interest rates lower the present value of future earnings and make debt financing for research and development more costly.

How much did Novavax, Ocular Therapeutix, and QuidelOrtho drop?

Novavax dropped 12.17% to $11.26, Ocular Therapeutix fell 6.91% to $6.87, and QuidelOrtho declined 7.19% to $12.91 during afternoon trading.

What is Novavax's 52-week high?

Novavax reached a 52-week high of $12.82 in October 2026. Despite recent losses, the stock remains up 57.1% year-to-date.